Specifications Product name: BPC-157 Synonyms: Body Protective Compound-157
Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation
A realistic earliest FDA decision window, assuming Phase 3 confirms the Phase 2 findings, is 2028
Analytical Constituents (%) Protein 8, Fat Content 5, Crude Fibre 0.2, Crude Ash 2.5, Moisture Content 82, Omega 6 1.3, Omega 3 0.3
Breakfast: Plain yogurt (proteins), homemade granola with rolled oats (carbohydrates), berries (fiber and vitamins), and a few almonds (fats)
The prescribing information for the generic version includes a warning about the increased risk of thyroid C-cell tumors